Balta Elizabeth 4

What Happened

• Elizabeth Balta, Chief Legal Officer and Corporate Secretary of Jade Biosciences (JBIO), received equity awards reported on 2026-02-12: 28,125 restricted stock units (RSUs) and a derivative award covering 168,750 shares (an option/award). Both awards were reported as acquired at $0.00 (no cash outlay reported).

Key Details

• Transaction date: 2026-02-12; Form 4 filed 2026-02-13 (timely).
• Awards: 28,125 RSUs (each converts to one share upon vesting) and a derivative option for 168,750 shares.
• Vesting (per footnotes): RSUs vest 25% on each of the first four anniversaries of 02/15/2026 (subject to continued service). The option vests 25% on 02/15/2027, then the remaining 75% vests in equal monthly installments over the next three years (subject to continued service).
• Price/value: Reported at $0.00 per share on the Form 4 (grant/award, not an open-market purchase or sale).
• Shares owned after transaction: Not specified in the information provided.
• Transaction code: A = Award/Grant. No 10b5-1 plan, tax-withholding sale, or late filing indicated.

Context

• These are compensation awards (not sales or open-market purchases). RSUs are a contingent right to receive shares when they vest; the derivative award is a right to purchase shares that vests over time. Such grants are common for executive compensation and reflect future vesting rather than an immediate change in market ownership.